{"id":785154,"date":"2023-09-20T09:07:25","date_gmt":"2023-09-20T13:07:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/"},"modified":"2023-09-20T09:07:25","modified_gmt":"2023-09-20T13:07:25","slug":"equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/","title":{"rendered":"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences<\/b><\/p>\n<p>LA JOLLA, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference.<\/p>\n<p>\nManagement will participate in a panel presentation at the Cantor Fitzgerald Conference where they will provide an overview of the Company\u2019s multi-cytokine inhibitor platform, and will give a full corporate and clinical overview including upcoming milestones at the LD Micro Main Event Conference. Management will be available for one-on-one meetings during both conferences.<\/p>\n<p><b>Conference: <\/b>Cantor Fitzgerald Global Healthcare Conference<br \/>\n<br \/><b>Location: <\/b>InterContinental Barclay Hotel, New York City<br \/>\n<br \/><b>Date: <\/b>Wednesday, September 27<br \/>\n<br \/><b>Time: <\/b>5:00 am Pacific Time | 8:00 am Eastern Time<\/p>\n<p><b>Conference: <\/b>LD Micro Invitational Conference<br \/>\n<br \/><b>Location: <\/b>Luxe Hotel, Los Angeles<br \/>\n<br \/><b>Date: <\/b>Tuesday, October 3<br \/>\n<br \/><b>Time: <\/b>11:00 am Pacific Time | 2:00 pm Eastern Time<\/p>\n<p>\nThe presentation at the LD Micro conference will be <strong>live-streamed<\/strong> on the event website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fme23.sequireevents.com%2F&amp;esheet=53558551&amp;newsitemid=20230920597056&amp;lan=en-US&amp;anchor=https%3A%2F%2Fme23.sequireevents.com%2F&amp;index=1&amp;md5=8c7b1982151ae558cee0582fa902df30\">https:\/\/me23.sequireevents.com\/<\/a>.<\/p>\n<p><b>About Equillium<\/b><\/p>\n<p>\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company\u2019s pipeline consists of the following novel first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under evaluation in a Phase 1 first-in-human clinical study to include healthy volunteers and celiac disease patients. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and a Phase 1b clinical study of patients with lupus\/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd. for the development and commercialization of itolizumab under an option and asset purchase agreement.<\/p>\n<p>\nFor more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.equilliumbio.com%2Fhome%2Fdefault.aspx&amp;esheet=53558551&amp;newsitemid=20230920597056&amp;lan=en-US&amp;anchor=www.equilliumbio.com&amp;index=2&amp;md5=42fa95ceec5114d68f550df14d9224fa\">www.equilliumbio.com<\/a>.<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p><i>Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as &#8220;anticipate&#8221;, &#8220;believe&#8221;, \u201ccould\u201d, \u201ccontinue\u201d, &#8220;expect&#8221;, &#8220;estimate&#8221;, \u201cmay\u201d, &#8220;plan&#8221;, &#8220;outlook&#8221;, \u201cfuture\u201d and &#8220;project&#8221; and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium\u2019s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks and uncertainties regarding whether, when and on what terms Equillium repurchases its shares of common stock under the program; changes in market conditions and alternative uses of Equillium\u2019s capital, including having to use cash in ways or on timing other than expected; the sufficiency of Equillium\u2019s capital to fund certain clinical development efforts and whether anticipated milestones are able to be achieved; whether Equillium is able to grow its business and increase stockholder value over time; and risks related to Ono\u2019s decision to exercise its option, if ever, to purchase itolizumab or terminate the asset purchase agreement.<\/i><i>These and other risks and uncertainties are described more fully under the caption &#8220;Risk Factors&#8221; and elsewhere in Equillium&#8217;s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission\u2019s website at <\/i><i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=53558551&amp;newsitemid=20230920597056&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=3d6f02f4dcb33356f5b099de4c1c905a\">www.sec.gov<\/a><\/i><i> and on Equillium\u2019s website under the heading \u201cInvestors.\u201d Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230920597056\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230920597056\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Michael Moore<br \/>\n<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>\n<br \/>619-302-4431<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@equilliumbio.com\">ir@equilliumbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230920597056\/en\/1894676\/3\/1_Equillium_Logo_400x400.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference. Management will participate in a panel presentation at the Cantor Fitzgerald Conference where they will provide an overview of the Company\u2019s multi-cytokine inhibitor platform, and will give a full corporate and clinical overview including upcoming milestones at the LD Micro Main Event Conference. Management will be available for one-on-one meetings during both conferences. Conference: Cantor Fitzgerald Global Healthcare Conference Location: InterContinental &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-785154","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference. Management will participate in a panel presentation at the Cantor Fitzgerald Conference where they will provide an overview of the Company\u2019s multi-cytokine inhibitor platform, and will give a full corporate and clinical overview including upcoming milestones at the LD Micro Main Event Conference. Management will be available for one-on-one meetings during both conferences. Conference: Cantor Fitzgerald Global Healthcare Conference Location: InterContinental &hellip; Continue reading &quot;Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-20T13:07:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences\",\"datePublished\":\"2023-09-20T13:07:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/\"},\"wordCount\":768,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/\",\"name\":\"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-09-20T13:07:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences - Market Newsdesk","og_description":"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference. Management will participate in a panel presentation at the Cantor Fitzgerald Conference where they will provide an overview of the Company\u2019s multi-cytokine inhibitor platform, and will give a full corporate and clinical overview including upcoming milestones at the LD Micro Main Event Conference. Management will be available for one-on-one meetings during both conferences. Conference: Cantor Fitzgerald Global Healthcare Conference Location: InterContinental &hellip; Continue reading \"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-20T13:07:25+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences","datePublished":"2023-09-20T13:07:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/"},"wordCount":768,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/","name":"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-09-20T13:07:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230920597056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-cantor-fitzgerald-global-healthcare-ld-micro-main-event-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Equillium to Present at the Cantor Fitzgerald Global Healthcare &amp; LD Micro Main Event Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=785154"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785154\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=785154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=785154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=785154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}